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Abstract 
Bipolar disorder is a chronic, cycling disorder affecting circa 2% of the population and whose 
pathophysiology is still largely unknown. It has been suggested that common treatments used for 
bipolar disorder have effects on the sex steroids yet sex steroids have also been shown to have 
widespread effects in the brain in systems of relevance to bipolar disorder. For example, DHEAS 
and progesterone have opposing effects on the glutamatergic and GABAergic systems essential 
for the regulation of other brain processes. The enzymes which are involved in the 
interconversions between these compounds are affected by a number of factors including 
polymorphisms in the genes coding for these enzymes. Papers 1-3 examine common 
polymorphisms in AKR1C4, HSD3B2 and SRD5A1, their relationships with 8-9 am serum 
hormone concentrations as well as to retrospectively but systematically collected data on 
symptoms which in animal and human studies have shown a possibility of connection to 
neurosteroid abnormalities. All investigations including history taking was done in euthymic 
phase of bipolar 1 or 2 disorders and included all available sources of information such as chart 
review and third party information. In paper 1, men but not women had lower serum progesterone 
concentrations during euthymic phase of bipolar disorder if they had exhibited manic irritability 
as opposed to euphoric mania. A gene variant of AKR1C4 was associated with lower progesterone 
concentrations and polymorphisms of this gene were also more frequent in the males with prior 
irritability during mood elevation. Paper 2 showed that these same polymorphisms that increased 
risk in men reduced the risk for paranoid ideation during mania in women. However in men, 
DHEAS and progesterone were both lower and this coupled at a trend level to a polymorphism in 
the HSD3B2 gene. In paper 3, depressive psychomotor agitation was coupled in both men and 
women to polymorphisms in SRD5A1. Yet only in men did one of the polymorphisms correspond 
to increased progesterone, a finding which was in line with the finding of higher progesterone if 
men had showed depressive psychomotor agitation.  
 
Testosterone has different effects to progesterone and DHEAS in the brain and has been 
implicated in psychosis, having effects on the dopamine system. In paper 4, parameters measuring 
testosterone effects at different points in development were investigated in women with bipolar 
disorder who had exhibited psychotic features and compared with those in women with bipolar 
disorder without such features as well as healthy control women. The A allele at rs6152 of the 
Androgen Receptor gene was associated with a greater risk of having had psychotic symptoms 
and was at a trend level associated with an earlier debut of psychotic symptoms. The D2:D4 
finger ratio which is believed to be a measure of prenatal testosterone milieu correlated with age 
of onset of psychosis indicating that high testosterone in the foetus predisposed the individual to 
an earlier psychosis onset but not to getting psychotic per se. A possible gene by drug interaction 
was found whereby the G allele rs6152 was associated with much higher bioavailable testosterone 
in the presence of neuroleptics. Upon further investigation this was explained by lower SHBG 
(sex hormone binding globulin) even in the presence of low doses of atypical neuroleptics. 
 
Taken together these studies suggest the involvement of sex steroids in mediating risk to 
particular phenotypes of presentation of bipolar disorder, rather than bipolar disorder itself. The 
symptoms correspond to those regarded to be of the so called mixed states. Whilst the studies are 
of reasonable size in ascertaining hormonal differences the studies are small with respect to the 
genetic data and need to be replicated in larger samples.   
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